Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients

類似資料

• Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients
  著者:: Sato, Yasuyoshi, 等
  出版事項: (2015)
• Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab
  著者:: Osumi, Hiroki, 等
  出版事項: (2015)
• Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer
  著者:: Ohhara, Yoshihito, 等
  出版事項: (2015)
• A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer
  著者:: Suenaga, Mitsukuni, 等
  出版事項: (2015)
• Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?
  著者:: Osumi, Hiroki, 等
  出版事項: (2015)